August 22, 2019
GlaxoSmithKline filed its first regulatory application for its renal anemia treatment daprodustat on August 21, in Japan, making it the third to reach this stage in the country among the class of drugs called hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors...read more